Comment on 'Predicting the response to infliximab from trough serum levels'

Gut

Volumn 59, Issue 9, 2010, Pages 1298-1299

  Bendtzen, K ^a   Steenholdt, C ^b   Ainsworth, M ^b   Thomsen, O O ^b   Brynskov, J ^b  

^a Rigshospitalet   (Denmark)

^b Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; DRUG ANTIBODY; INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY BLOOD LEVEL; ANTIGEN ANTIBODY COMPLEX; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG RESPONSE; HUMAN; LETTER; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; BLOOD; COLITIS, ULCERATIVE; DRUG MONITORING; PROCEDURES;

ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG MONITORING; GASTROINTESTINAL AGENTS; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956117451     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2009.206805     Document Type: Letter

References (4)

1. Rutgeerts P, Vermeire S, van Assche G. Predicting the response to infliximab from trough serum levels (commentary). Gut 2010;59:7-8.
2. Bendtzen K. Immunogenicity of anti-TNF antibodies. In: van de Weert M, Møller EH, eds. Immunogenicity of biopharmaceuticals. Vol 8, New York: Springer, 2008:189-203.
3. Bendtzen K, Ainsworth MA, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:774-81.
4. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008;103:944-8. (Pubitemid 351501078)